Longeveron Granted U.S. Patent for Stem Cell Therapy Targeting Aging-Related Frailty
Longeveron Inc. has been granted a U.S. patent for its mesenchymal stem cell therapy aimed at treating aging-related frailty. The patent, valid until 2038, covers the use of isolated allogeneic MSCs to alleviate symptoms like weakness and exhaustion in older patients. The company's lead therapy, laromestrocel, has shown promising results in two clinical trials focused on this condition.
Longeveron Inc. announced that the United States Patent and Trademark Office has granted a patent for methods of treating aging-related frailty in patients with inflammaging using its proprietary mesenchymal stem cell (MSC) therapy. The patent, which is valid through 2038, covers the administration of isolated allogeneic MSCs to address symptoms such as weakness, low physical activity, slowed motor performance, exhaustion, and unintentional weight loss in older individuals. The company’s lead MSC therapy, laromestrocel, has shown positive initial results in two clinical trials targeting aging-related frailty. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longeveron Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573845-en) on November 12, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
